Expect near-term selling pressure from the dilutive offering. Monitor the stock for potential support around the offering price. The company's cash position strengthens, reducing near-term financing risk.
ORKA drugs
ORKA drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 29 $68.10entry
- T+1 · 7mo ago 0.00%α −1.02% · $68.10
- T+5 · 7mo ago +1.25%α −1.86% · $68.95
- T+20 · 6mo ago −14.85%α −20.31% · $57.99
- T+60 · 4mo ago +35.33%α +31.22% · $92.16
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Oruka Therapeutics priced an upsized underwritten public offering of 9.66 million shares at $72.50 per share, raising approximately $700.4 million in gross proceeds. The substantial dilution (~18% of current shares outstanding) is likely to pressure the stock near term, though the capital bolsters its clinical-stage pipeline.
Key Financial Metrics
Key Facts
- Offering of 9,660,000 shares at $72.50 per share
- Gross proceeds of ~$700.4 million
- Underwriters have 30-day option for additional 1,449,000 shares
- Expected closing on April 30, 2026
- Dilution of approximately 18.4% (21.1% including greenshoe)
Financial Impact
~$700.4M gross proceeds; dilution of ~18% of pre-offering shares outstanding
Risk Factors
- Further dilution if underwriters exercise the greenshoe option
- Stock overhang as new shares enter the market
- Clinical-stage biotech with no approved products; execution risk remains
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3283352 |
Track record
40 reports on ORKA
6 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +80.05% at T+60 after the Jun 1, 2026 report. 10 of 10 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $102.46 Now $99.24 −3.14% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $104.40 Now $99.24 −4.94% settles Dec 15
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $106.15 Now $99.24 −6.51% settles Dec 15
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $104.89 Now $99.24 −5.39% settles Dec 15
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $109.50 Now $99.24 −9.37% settles Dec 9
- Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
- Nov 2, 202614d ago 144 Neutral 3/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
- Oct 26, 202621d ago 8-K Bullish 6/10 Entry $90.33 Now $99.24 +9.86% settles Nov 23
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers